FOR IN VITRO AND PRE-CLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE
Recovery

BPC-157 10mg

10mg recovery research peptide

From€39.00
In Stock · Ships within 48h
Reviews coming soonBe among the first to share your research experience.
Download Certificate of Analysis
  • EU Dispatch
  • CoA Included — Every Batch
  • Discreet Packaging
Purity≥98% HPLC
FormLyophilised Powder
Storage2–8°C
OriginEuropean Stock
DispatchWithin 48h
SKUUL-BPC-10MG
≥98% PureHPLC verified
HPLC TestedDual identity check
EU DispatchShips within 48h
CoA Incl.Every batch
Research Profile

Why Body Protection Compound-157 Fascinates Researchers

BPC-157 — full designation Body Protection Compound-157 — is a synthetic pentadecapeptide of fifteen amino acids, its sequence a partial excerpt of the Body Protection Compound isolated from human gastric juice. Since its first characterisation in the early 1990s, it has accumulated one of the most extensive preclinical dossiers in peptide science.

Origin & Structural Identity

The parent protein from which BPC-157 is derived is found in the protective lining of the gastric mucosa, a tissue subject to perpetual chemical insult. Researchers originally identified it while investigating endogenous mechanisms that allow stomach epithelium to withstand acid and enzymatic degradation. The synthetic fifteen-residue fragment — Pro-Pro-Pro-Pro-Pro-Pro-Gly-Glu-Pro-Pro-Pro-Pro-Pro-Gly-Lys — proved to be both stable and highly active in isolation, surviving the proteolytic environment that destroys most natural peptides.

Mechanism of Action

Preclinical investigation has pointed toward BPC-157 engaging multiple signalling cascades simultaneously. Studies in rodent models have documented interactions with the nitric oxide (NO) system, where the compound appears to modulate eNOS expression and downstream vascular tone. Of particular interest to connective tissue researchers is its apparent influence on growth factor receptor pathways: work by Sikiric and colleagues identified upregulation of VEGFR2 and FGFR in tendon fibroblasts, suggesting a role in vascular and structural remodelling at sites of injury.

Parallel work in gastrointestinal research has explored BPC-157's interaction with the dopaminergic and serotonergic systems, as well as its apparent capacity to modulate prostaglandin synthesis — findings that have informed mechanistic models of its cytoprotective activity.

Research Applications & Status

The preclinical literature on BPC-157 spans several distinct biological territories. Musculoskeletal research has examined healing dynamics in transected Achilles tendons, severed quadriceps, and rotator cuff injury models, consistently reporting accelerated restoration of biomechanical integrity. Gastrointestinal research has explored its protective effects across a range of mucosal insult models, from NSAID-induced damage to stress-induced ulceration. Neurological studies have investigated modulation of glutamate-mediated excitotoxicity and dopamine system function in rodent preparations.

A notable feature of the existing literature is the compound's apparent stability across administration routes — subcutaneous, intragastric, and intraperitoneal — a characteristic that has made it a practical tool for in vivo study design.

Despite its substantial preclinical footprint, BPC-157 remains a research compound without regulatory approval for human use. All studies cited in the scientific literature were conducted under controlled laboratory conditions using animal models or in vitro cell cultures. Researchers working with BPC-157 are advised to consult the most current primary literature and to operate within applicable institutional and regulatory frameworks.

This content is for informational purposes only and reflects the state of preclinical research. It does not constitute medical advice, endorsement of human use, or therapeutic claims of any kind.

Manufacturing Standards

Our Quality Commitment

HPLC Verified

Purity confirmed by High-Performance Liquid Chromatography at an accredited EU laboratory.

≥98% Purity

Every batch meets or exceeds 98% purity. CoA available for verification before dispatch.

Batch Traceability

Each vial is traceable to its synthesis batch, testing date, and analytical records.

Cold Chain Storage

European stock stored at optimal temperature from synthesis to dispatch.

48h EU Dispatch

Orders ship from EU stock within 48 hours with discrete, temperature-appropriate packaging.

CoA Included

Certificate of Analysis issued for every batch, available for download on request.

Download CoA for BPC-157 10mg
Peer-Reviewed Literature

Key Scientific Studies

Peer-reviewed research supporting Body Protection Compound-157 investigation.

[01]
Sikiric P, Seiwerth S, Rucman R, et al. (2018) — Current Pharmaceutical Design

“Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract”

This comprehensive review synthesises over two decades of preclinical data on BPC-157 across gastrointestinal and musculoskeletal applications. Authors document consistent cytoprotective effects in mucosal injury models and propose mechanistic links to the NO-system and growth factor receptor modulation.

View on PubMed
[02]
Gwyer D, Wragg NM, Wilson SL. (2019) — Cell and Tissue Research

“Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing”

A systematic examination of BPC-157's effects on tendon, ligament, and muscle repair in rodent models. The authors report significant improvements in biomechanical tensile strength and histological markers of organised collagen deposition at treated injury sites relative to controls.

View on PubMed
[03]
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. (2011) — Journal of Applied Physiology

“The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration”

In vitro work demonstrating BPC-157's capacity to enhance tendon fibroblast proliferation, migration, and survival following serum deprivation. The study identifies dose-dependent upregulation of F-actin cytoskeletal organisation and FAK/paxillin signalling, providing a cellular basis for observed in vivo healing effects.

View on PubMed
[04]
Sikiric P, Seiwerth S, Rucman R, et al. (2016) — Current Pharmaceutical Design

“Cytoprotection-time to re-examine its meaning and role: BPC 157 peptide therapy”

A conceptual and experimental review reframing BPC-157's activity within a broader cytoprotective paradigm. The paper argues for an integrated model incorporating vascular, neural, and inflammatory pathway modulation, supported by data from ulcer, liver, and brain injury models.

View on PubMed
[05]
Vukovic S, Ivica J, Drmic D, et al. (2020) — Biomolecules

“BPC 157 and the central dopamine system: recovery of function in 6-OHDA lesion model”

Investigation into BPC-157's effects on dopaminergic pathways using a 6-hydroxydopamine lesion rodent model. The study reports partial functional recovery in motor performance correlated with changes in dopamine metabolite ratios, suggesting interaction with central catecholaminergic circuitry.

View on PubMed

All studies referenced are independent third-party research. UNIK LAB makes no claims regarding the therapeutic efficacy of any compound and does not represent or endorse the conclusions of cited studies. All referenced research was conducted under controlled laboratory or clinical conditions; results may not be predictive of effects in other experimental contexts.

Common Questions

Research FAQ

Answers to the most frequently asked questions about Body Protection Compound-157.

Same Category

Similar Compounds

Other Recovery research compounds from our catalogue.

Your Longevity Research Guide Awaits

Subscribe to receive new compound profiles, CoA updates, and curated research digests — delivered directly to your inbox.